### GHRP-6 (GHRP-6) for Injection
**HIGHLIGHTS OF PRESCRIBING INFORMATION**
These highlights do not include all the information needed to use GHRP-6 safely and effectively. See full prescribing information for GHRP-6.
GHRP-6 injection, for subcutaneous use
**INDICATIONS AND USAGE**
GHRP-6 is a hexapeptide indicated for investigational use in stimulating growth hormone release, increasing appetite, and aiding muscle gain and recovery in performance enhancement settings. Not approved for human therapeutic use in many jurisdictions; consult local regulations (1).
**DOSAGE AND ADMINISTRATION**
– Reconstitute lyophilized powder with bacteriostatic water.
– Adult males: 100 mcg to 300 mcg per day, divided into 2-3 doses.
– Adult females: 100 mcg to 200 mcg per day, divided into 2-3 doses (2.1).
– Cycle duration: Typically 4 to 8 weeks for bulking.
**DOSAGE FORMS AND STRENGTHS**
Lyophilized powder: 5 mg per vial (3).
**CONTRAINDICATIONS**
– Hypersensitivity to GHRP-6 or any component of the formulation (4).
– Obesity due to appetite stimulation (4).
– Active malignancy due to growth hormone effects (4).
**WARNINGS AND PRECAUTIONS**
– Water retention: May cause edema; monitor fluid status (5.1).
– Elevated prolactin/cortisol: Monitor hormone levels (5.2).
– Injection site reactions: Monitor for irritation or swelling (5.3).
– Limited long-term safety data: Use cautiously in chronic conditions (5.4).
**ADVERSE REACTIONS**
Common adverse reactions include increased hunger, injection site reactions, and tiredness (6).
**DRUG INTERACTIONS**
– Growth hormone secretagogues: May amplify effects; use cautiously (7.1).
**USE IN SPECIFIC POPULATIONS**
– Pregnancy: Insufficient data; avoid use (8.1).
– Lactation: Excretion unknown; not recommended (8.2).
– Pediatric use: Safety not established (8.4).
– Geriatric use: Monitor for organ dysfunction (8.5).
Revised: 08/2025
**FULL PRESCRIBING INFORMATION**
**1 INDICATIONS AND USAGE**
GHRP-6 is indicated for investigational use in adults to stimulate growth hormone (GH) release, increase appetite for caloric surplus, improve recovery, enhance fat metabolism, boost immune function, and improve sleep quality. It is commonly used in bulking cycles to support muscle gain. This product is not approved for clinical use and should be administered under medical supervision.
**2 DOSAGE AND ADMINISTRATION**
**2.1 Recommended Dosage**
Reconstitute 5 mg vial with 1-2 mL bacteriostatic water. Administer subcutaneously, preferably in the abdomen or thigh, 2-3 times daily to mimic pulsatile GH release.
– Males: 100 mcg to 300 mcg daily, divided into 2-3 doses (e.g., 100 mcg morning, noon, evening).
– Females: 100 mcg to 200 mcg daily, divided into 2-3 doses.
– Cycle duration: Typically 4 to 8 weeks, adjusted based on response and tolerance. Discontinue if adverse effects occur.
**2.2 Preparation and Handling**
Use sterile technique to reconstitute and draw doses. Inspect reconstituted solution for clarity; do not use if discolored or particulate matter is present.
**3 DOSAGE FORMS AND STRENGTHS**
Supplied as lyophilized powder containing 5 mg GHRP-6 per single-use vial.
**4 CONTRAINDICATIONS**
GHRP-6 is contraindicated in:
– Patients with known hypersensitivity to GHRP-6 or excipients (e.g., mannitol).
– Patients with obesity, as appetite stimulation may exacerbate weight gain.
– Patients with active malignancy due to potential promotion of growth hormone and IGF-1, which may exacerbate tumor growth.
**5 WARNINGS AND PRECAUTIONS**
**5.1 Water Retention**
May cause edema due to growth hormone effects, potentially exacerbating cardiac or renal conditions. Monitor fluid status and discontinue if significant swelling occurs.
**5.2 Elevated Prolactin/Cortisol**
May increase prolactin or cortisol levels, potentially leading to gynecomastia or stress-related effects. Monitor hormone levels and adjust therapy as needed.
**5.3 Injection Site Reactions**
May cause localized pain, redness, or swelling at the injection site. Rotate injection sites and monitor for signs of infection or severe reactions.
**5.4 Limited Long-Term Safety Data**
Long-term effects in humans are not well-established; use with caution in patients with chronic conditions or for prolonged periods. Regular monitoring is recommended.
**6 ADVERSE REACTIONS**
Reported adverse reactions include:
– Gastrointestinal: Increased hunger, mild nausea.
– General: Tiredness, fatigue.
– Local: Injection site pain, erythema, or swelling.
– Endocrine: Potential gynecomastia due to prolactin elevation (rare).
Serious reactions may include hypersensitivity responses or significant hormonal imbalances.
**7 DRUG INTERACTIONS**
**7.1 Growth Hormone Secretagogues**
Concurrent use with other GHRH or GHRP peptides (e.g., CJC-1295) may amplify growth hormone release, increasing the risk of side effects. Use with caution and monitor closely.
**8 USE IN SPECIFIC POPULATIONS**
**8.1 Pregnancy**
No adequate studies in pregnant women; potential risks to the fetus are unknown due to growth hormone effects. Avoid use during pregnancy.
**8.2 Lactation**
Excretion in breast milk is unknown; breastfeeding is not recommended due to potential risks to the infant.
**8.4 Pediatric Use**
Safety and efficacy not established in pediatric patients; use is not recommended due to potential effects on growth plates.
**8.5 Geriatric Use**
Limited data available; monitor for age-related organ dysfunction, particularly cardiovascular or endocrine issues.
**9 DRUG ABUSE AND DEPENDENCE**
No evidence of abuse or dependence potential with GHRP-6, but misuse for performance enhancement may occur. Monitor for inappropriate use.
**10 OVERDOSAGE**
Symptoms of overdose may include excessive hunger, fatigue, or hormonal imbalances. No specific antidote exists; treat symptomatically and discontinue use immediately.
**11 DESCRIPTION**
GHRP-6 is a synthetic hexapeptide that stimulates growth hormone release and appetite. It is supplied as a white lyophilized powder, soluble in bacteriostatic water for injection. Each vial contains 5 mg GHRP-6, with mannitol as a stabilizer. Half-life: Approximately 30 minutes. Note: Ethyl oleate and ricinus oil are not used in this formulation, as it is water-based.
**12 CLINICAL PHARMACOLOGY**
**12.1 Mechanism of Action**
GHRP-6 stimulates growth hormone release from the pituitary, increasing IGF-1 levels, promoting anabolism, appetite, and recovery.
**12.3 Pharmacokinetics**
Rapidly absorbed after subcutaneous injection; short half-life of approximately 30 minutes; metabolized and excreted rapidly, primarily via urine.
**13 NONCLINICAL TOXICOLOGY**
Limited data available; animal studies suggest low toxicity but potential for hormonal effects. No human carcinogenicity data available.
**16 HOW SUPPLIED/STORAGE AND HANDLING**
5 mg lyophilized powder in single-use vials. Store refrigerated at 2°-8°C (36°-46°F). Reconstituted solution stable for up to 14 days refrigerated. Protect from light. Keep out of reach of children.
*Manufactured by: Medi Pharma*
